What is the difference between small molecule drugs and biologics?

Small molecules are smaller, chemically defined compounds made via straightforward synthesis and are generally stable and consistent across manufacturing. Biologics are larger, complex biological structures produced in cell lines; their processes are variable, harder to reproduce, and greatly impact structure and properties.

Why is life sciences R&D becoming more multidisciplinary?

Companies are pursuing a broad range of drug modalities as the divide between small molecules and biologics fades, driving changes in investment strategies, treatment options, and collaboration across R&D teams.

How do small molecule drugs differ from biologics in permeability?

Small molecules have higher permeability and are easier to reach intracellular targets, while biologics are less permeable and more challenging to reach targets.

What are the typical administration routes and PK/PD differences between small molecules and biologics?

Small molecules can often be administered orally with more predictable PK and PD, faster time to peak concentration via blood distribution, and shorter half-life. Biologics typically require injection or infusion, have PK and PD that are more difficult to predict with slower time to peak via lymphatic and blood distribution, and longer half-life.

How do stability and storage requirements compare for small molecules versus biologics?

Small molecules vary in polarity, are heat stable and generally stable, and can be stored at room temperature. Biologics are generally polar, heat sensitive, degradable, and typically require refrigeration; modifications can help improve degradation.

How do generics and biosimilars differ in exclusivity periods and cost reductions?

Small molecules face a well-established generic market with 5-year exclusivity before generic competition and around 80% cost reduction. Biologics have a burgeoning biosimilar market with 12 years of exclusivity and about 20–30% cost reductions for biosimilars.

Are biologics generally more expensive than small molecules?

Yes. Small molecules are generally lower cost, while biologics are generally higher cost.

A Complete Guide to Small Molecule Drugs vs Biologics: Key Differences and Where They're Merging

The traditional distinctions between small molecule drugs and biologics are diminishing as pharmaceutical companies diversify their portfolios, invest in multidisciplinary R&D, and develop hybrid modalities like antibody drug conjugates, leading to integrated manufacturing capabilities and evolving treatment options.

Small molecule drugs and biologics have long been viewed as markedly different therapeutic options, each with unique development pathways, most suitable indications, and distinct advantages and disadvantages. Traditionally, companies specialized in one area, and investment trends shifted between the two. However, the distinction between small molecule and biologics drugs is becoming less pronounced as research and development (R&D) becomes more multidisciplinary.

Research is Becoming Multidisciplinary

Increasingly, companies are pursuing a broad range of drug modalities, recognizing that this approach may be the best investment and, more importantly, best for patients who need innovative and cost-effective treatments. As the divide fades, changes are occurring in investment strategies, treatment options, and R&D team collaboration.

1. Companies are Diversifying

Many companies, from big pharma to manufacturers, are expanding into both small molecule drug and biologics markets. The number of new entity approvals for small molecules and biologics in the US has started to equalize. Examples include:

Novartis building a new research center in Switzerland to extend biologics innovation.
Amgen acquiring Horizon Therapeutics to expand biologics offerings.
Manufacturers like Lonza, WuXI STA, and Catalent expanding biologics manufacturing capabilities, including mRNA and oligonucleotides.
Samsung Biologics increasing global biologics manufacturing capacity.
Continued investment in small molecule drug manufacturing by companies like HAS Healthcare Advanced Synthesis and Cambrex.

Many companies are breaking down barriers between their chemistry, manufacturing, and controls (CMC) teams to facilitate knowledge sharing between small molecule and biologics groups.

2. Modalities are Evolving

The lines between treatments are blurring. Chemically-modified biologics, such as antibody drug conjugates that combine small molecule drugs and biologics, are becoming more common. This requires increased collaboration between research groups. Multidisciplinary collaboration helps overcome limitations of biologics, such as immunogenicity and degradation, by chemically modifying biologic structures or using protective drug-delivery vehicles.

Research is also exploring novel applications of small molecules for targets traditionally addressed by biologics, such as:

Modulating RNA-based processes and gene expression
Acting as targeted, dual-binding protein degraders to eliminate problematic proteins
Functioning as molecular glue compounds to interfere with protein-protein interactions in diseases like cancer and neurodegenerative conditions

For hard-to-treat diseases, both small molecule and biologic treatment options are available. For example, spinal muscular atrophy (SMA) can be treated with either Spinraza (an RNA therapeutic) or Evrysdi (a small molecule drug). Rheumatoid arthritis treatments include both biologics and small-molecule JAK inhibitors.

3. Teams are Collaborating

As small molecule drug discovery and biologics R&D blend, multidisciplinary collaboration is increasingly important. Modality-centric teams must collaborate and share data across departments, partner sites, and locations. However, many companies still use separate informatics systems and siloed databases, creating inefficiencies. The solution is an R&D platform that supports both small molecule drug discovery and biologics R&D.

Small Molecule Drugs vs Biologics Comparison

Item	Small Molecule Drugs	Biologics
Size	Smaller with lower molecular mass	Larger with higher molecular mass
Structure	Chemical compounds; simple, definable, stable; consistent across manufacturing processes	Biological structures; complex, heterogeneous, degradable; highly impacted by manufacturing processes
Mechanism of Action (MOA)	Interfere with biochemical reactions (e.g., receptor proteins, ion channels, kinases); exact MOA sometimes unknown	Impact biologic cellular and genetic processes (e.g., protein-protein interactions, protein production, gene expression); thorough understanding of MOA necessary
Disease Target	Acute and chronic conditions (e.g., pain, fever, infection, psychiatric conditions, allergies, cardiovascular health)	Complex and hard-to-treat diseases (e.g., cancer, autoimmune disease, metabolic disease, genetic disorders)
Examples	Antibiotics, proton-pump inhibitors, beta blockers, calcium channel blockers, opioids, benzodiazepines, SSRIs, antihistamines, synthetic steroids, kinase inhibitors, etc.	Nucleic acids (e.g., RNA), peptides, enzymes, proteins, antibodies (e.g., monoclonal antibodies), cell therapies (e.g., CAR-T), vaccines, hormones, blood products
Selectivity	Lower selectivity; off-target binding more likely	Higher specificity; off-target effects unlikely
Safety	Potential toxicity due to off-target effects; higher likelihood of drug-drug interactions (due to ADME processes)	Lower toxicity overall; greater likelihood of immune response (immunogenicity); less prone to drug-drug interactions (due to ADME profile), though some potential to impact drug-metabolizing enzymes
Production	Straightforward chemical synthesis; standardizable; processes easier to reproduce and quality control; replicating exact structure across different manufacturing processes is probable	Requires cell line production and live organisms; variable complex processes; processes harder to reproduce and QC; process greatly impacts structure; difficult to attain exact copies from batch to batch
Structural Assessment	Highly determinable via traditional analytic methods	Elusive and typically not fully determinable; structural determination and quantification challenging
Permeability	Higher permeability, easier to reach intracellular targets	Less permeable, more challenging to reach targets
Administration	Oral administration possible; predictable PK and PD; animal and assay models well established; faster time to peak concentration via blood distribution; shorter half-life	Injection or infusion in a care setting typically needed; PK and PD difficult to predict; impacted by size, structure, folding, and surface charge; modifications can improve profile; animal and assay models less developed; slower time to peak concentration via lymphatic and blood distribution; longer half-life
Stability	Polarity varies; heat stable; stable	Generally polar; heat sensitive; degradable; modifications can help improve degradation
Storage	Room temperature	Refrigeration
Exclusivity / Generics	Well-established generic market; easier to replicate; straightforward requirements for generic equivalence; 5-year exclusivity before generic competition; generic cost reduction ~80%	Burgeoning biosimilar market; more difficult to replicate; more complex requirements for biosimilarity; 12 years exclusivity before generic competition; biosimilar cost reduction ~20-30%
Price	Generally lower cost	Generally higher cost

References

1.Kesselring, L. “The Differences Between Small Molecule Drugs and Biological Drugs?” Emory Technology Transfer Blog. February 16, 2021.
2.Buvailo, A. “Will Biologics Surpass Small Molecules in the Pharmaceutical Race?” February 21, 2022.
3.Lai, Y. and Zhong, X. “Special Section on Pharmacokinetics and ADME of Biological Therapeutics–Editorial.” Drug Metabolism and Disposition. June 1, 2022, 50 (6) 819-821.
4.Vargason, A.M., Anselmo, A.C. & Mitragotri, S. “The evolution of commercial drug delivery technologies.” Nat Biomed Eng 5, 951–967 (2021).
5.Boomershine, W. “Structural Characterization of Biologics using High-Res Mass Spec.” (Accessed March 3, 2023).
6.“What are the challenges of LC–MS strategies for biologic quantitation? How do you avoid these and what solutions have you used to overcome them?” Bioanalysis Zone. June 2, 2020.
7.The Generic Drug Approval Process. US Food & Drug Administration. March 17, 2022.
8.Frequently Asked Questions on Patents and Exclusivity. US Food & Drug Administration. February 5, 2020.
9.Chen, Y., Monnard, A., da Silva, J. “An inflection point for biosimilars.” McKinsey & Company. June 7, 2021.
10.Andrews, M. “Biosimilar Drugs Are Cheaper Than Biologics. Are They Similar Enough to Switch?” KHN News. September 23, 2021.
11.Guidance for Industry: Reference Product Exclusivity for Biological Products. US Food & Drug Administration. August 2012.
12.Biosimilars: Review and Approval. US Food & Drug Administration. December 13, 2022.
13.Beall, R.F., Hwang, T.J. & Kesselheim, A.S. “Pre-market development times for biologic versus small-molecule drugs.” Nat Biotechnol 37, 708–711 (2019).
14.Makurvet, F.D. “Biologics vs. small molecules: Drug costs and patient access.” Medicine in Drug Discovery 9 (2021) 100075.
15.Research and Development in the Pharmaceutical Industry. US Congressional Budget Office. April 2021.